nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2006 | Original article

Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [¹⁸F]fluorodeoxyglucose positron emission tomography

verfasst von: Ukihide Tateishi, Umio Yamaguchi, Kunihiko Seki, Takashi Terauchi, Yasuaki Arai, Tadashi Hasegawa

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was conducted to investigate whether¹⁸F-fluorodeoxyglucose (FDG) uptake, quantified by positron emission tomography (PET), correlates with histological variables including tumour grade, cell proliferation, cell cycle control integrity and glucose metabolism in patients with bone and soft tissue sarcomas.

Methods

Eighty-two patients clinically suspected of having a bone or soft tissue sarcoma underwent FDG PET within 1 week prior to operation and 63 patients (mean age 48 years, range 18–74 years) were enrolled in the complete analysis. We excluded 17 patients with pathologically confirmed benign tumours and two patients with uncontrolled diabetes or concomitant malignancy from data analysis. Maximum and average standardised uptake values (SUVs) of the primary lesion were compared with histological variables including tumour differentiation, the presence of necrosis, MIB-1 score, mitotic score, p53 overexpression, MIB-1 grade, mitotic grade and GLUT-1 expression.

Results

Significant correlations were found between maximal and mean SUVs and MIB-1 grade, mitotic grade, MIB-1 score, tumour differentiation and mitotic score. The mean and maximal SUVs were significantly higher in tumours with p53 overexpression than in those without p53 overexpression (p<0.0001). GLUT-1-positive tumours had significantly higher mean (6.5±4.2 vs 1.1±0.2, p=0.006) and maximal SUVs (8.8±5.4 vs 1.7±0.5, p=0.005) than the GLUT-1-negative tumours. GLUT-1 intensity correlated positively with both mean (r=0.500, p<0.0001) and maximal SUVs (r=0.509, p<0.0001). Mu ltiple linear regression analysis showed a significant correlation between maximal SUV and MIB-1 grade (p<0.0001).

Conclusion

The enhanced glucose metabolism, as determined by SUV, is a strong index of tumour grade in bone and soft tissue sarcomas.

Weiss SW, Goldblum JR Enzinger and Weiss’s soft tissue tumors. 4th edn. St. Louis: Mosby, 2001

Costa J, Wesley RA, Glastein E, Rosenberg SA The grading of soft tissue sarcomas. Results of a clinicopathologic correlation in a series of 163 cases. Cancer 1984;53:530–541PubMedCrossRef

Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y, Hirohashi S Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 2002;95:843–851PubMedCrossRef

Hasegawa T, Yamamoto S, Nojima T, Hirose T, Nikaido T, Yamashiro K, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol 2002;33:111–115PubMedCrossRef

Bredella MA, Caputo GR, Steinbach LS Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentogenol 2002;179:1145–1150

Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257–261PubMed

Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215–1220PubMed

Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279–1287PubMed

Ioannidis JP, Lau J ¹⁸F-FDG PET for the diagnosis of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003;44:717–724PubMed

10.

Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83–101PubMedCrossRef

11.

Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC Comparison of [¹⁸F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25(1):11–17PubMedCrossRef

12.

Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, Manabe T, Saga T [¹⁸F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369–379PubMedCrossRef

13.

Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996;37(6):1042–1047PubMed

14.

Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344–1348PubMed

15.

Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997;38:1337–1344PubMed

16.

Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase¹⁸F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173–180PubMed

17.

Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015–1024PubMedCrossRef

18.

Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003;23:3263–3272PubMed

19.

Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al.¹⁸F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–29PubMed

20.

Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004;109:926–932PubMedCrossRef

21.

Ito S, Nemoto T, Satoh S, Sekihara H, Seyama Y, Kubota S Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1. Arch Biochem Biophys 2000;373:72–82PubMedCrossRef

22.

Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350–362PubMed

23.

Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 1994;73:2499–2505PubMedCrossRef

24.

Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994;145:345–355PubMed

25.

Toffoli G, Doglioni C, Cernigoi C, Frustaci S, Perin T, Canal B, Boiocchi M p53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness. Ann Oncol 1994;5:167–172PubMed

26.

Medina RA, Owen GI Glucose transporters: expression, regulation and cancer. Biol Res 2002;35:9–26PubMedCrossRef

27.

Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorm U, Ewerbeck V, et al.¹⁸F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004;45:1528–1535PubMed

28.

Borbely K, Fulham MJ, Brooks RA, DiChiro G PET-fluorodeoxyglucose of cranial and spinal neuromas. J Nucl Med 1992;33:1931–1934PubMed

29.

Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR Am J Roentogenol 2004;182:971–974

Titel: Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography
verfasst von: Ukihide Tateishi
Umio Yamaguchi
Kunihiko Seki
Takashi Terauchi
Yasuaki Arai
Tadashi Hasegawa
Publikationsdatum: 01.06.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0044-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′

Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison

Robustness of estimation of differential renal function in infants and children with unilateral prenatal diagnosis of a hydronephrotic kidney on dynamic renography: How real is the supranormal kidney?

Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice

Feasibility of in vivo dual-energy myocardial SPECT for monitoring the distribution of transplanted cells in relation to the infarction site

Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study